Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Co. Ltd
Collaboration will allow OCB’s suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People’s Republic of China
Oxford, UK, April 2017 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company developing tests that allow medicines to be personalised for the benefit of the cancer patient, has today announced a strategic collaboration with My-BioMed Biotechnology Co. Ltd. based in Ningbo, Zhejiang, China.
The partnership includes a licencing deal that will allow My-BioMed Biotechnology Ltd to access OCB’s ColoTox, ColoProg and ColoPredict technologies and to drive uptake across the People’s Republic of China via a purpose built biomedical laboratory in Ningbo Meishan FTZ.
OCB has developed a suite of diagnostic tests for colorectal cancer (CRC) to personalise current treatment pathways and plans to develop similar tests for other cancer indications. As of 2015, 274,000 new cases of colorectal cancer are diagnosed every year in the Peoples Republic of China, 190,400 of these cases prove fatal.
My-BioMed (MBM) is a leading precision medicine organisation, focussed on bringing global innovation to the Chinese market. The team at MBM has extensive experience in product development and launch including clinical development, regulatory strategy, clinical laboratory services, sales and marketing. MBM’s core business model is driven by patient and clinician needs.
Jackson Zhu, CEO of MBM, commented “We are very happy to launch the first three proprietary CRC diagnostic tests discovered at Oxford University and developed by OCB, aimed at specifically benefitting patients in China. Through this partnership MBM and OCB have solidified a long term commitment to China, with the aim of developing and launching a suite of unique diagnostic products.”
Prof David Kerr, Chief Medical Officer of OCB, commented “Our strategic partnership with MBM will allow patients across China to access OCB’s suite of precision oncology diagnostic technologies. We are looking forward to working closely with MBM to tailor our offerings to the specific needs of the Chinese market and building a robust product pipeline of diagnostics specifically aimed at the Chinese population. This is an important step in our mission to drive global access to technologies that allow patient stratification and individually tailored treatment pathways.”
About Oxford Cancer Biomarkers
Oxford Cancer Biomarkers translates ground-breaking scientific discovery into predictive biomarker diagnostic products that allow medicines to be personalised for the benefit of the cancer patient. Oxford Cancer Biomarkers is a spin-out of the University of Oxford and has strong links with the Medical Sciences Division in Oxford University. The company was founded by Nick La Thangue, Ph.D., Chair of Cancer Biology at Oxford University and David Kerr, CBE, D.Sc., M.D. FMedSci, Professor of Cancer Medicine at Oxford University. Investors in OCB include Longwall Venture Partners LLP, Esperante BV and the University.
For more information, please visit: http://www.oxfordcancerbiomarkers.com
Oxford Cancer Biomarkers Ltd
Tel: +44 1865 784743
Nick La Thangue, CEO / David Oxlade, Chairman
About Ningbo My-BioMed Biotechnology Co.,Ltd.
In pursuit of its vision of “Bridging World Innovation in Precision Medicine”, My-BioMed (MBM) is dedicated to providing personalized solutions to clinicians and patients, and to building an integrated commercialization platform for innovation.
Supported by Ningbo Meishan’s Healthcare industry development strategy, MBM, established in May 2016, has attracted a group of talented individuals with experience across a range of disciplines including; business development, market access, clinical development, registration, clinical lab services, sales and marketing. Located at Ningbo Meishan Free Trade Port, My-BioMed Clinical Laboratory, MBM wholly owned subsidiary, has been granted pre-approval from the Health and Family Plan Commission, and will be certified within this year.
Ningbo My-BioMed Biotechnology Co., Ltd.
Jackson Zhu, CEO